ArticleJournal of clinical microbiology2003
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
Article in Journal of clinical microbiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis.Scientific reports · 2020Pooled it
- A five-year survey of dematiaceous fungi in a tropical hospital reveals potential opportunistic species.PloS one · 2014Trial
- Microscopic evaluation, molecular identification, antifungal susceptibility, and clinical outcomes in fusarium, Aspergillus and, dematiaceous keratitis.BioMed research international · 2013Trial
- Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.Antimicrobial agents and chemotherapy · 2009Trial
- Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Antimicrobial agents and chemotherapy · 2007Trial
- Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.Antimicrobial agents and chemotherapy · 2006Trial
- Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.Antimicrobial agents and chemotherapy · 2006Trial
- Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.Antimicrobial agents and chemotherapy · 2005Trial
- Azole drugs have differential efficacy in varied models of immunosuppression in larval zebrafish hosts.Future microbiology · 2025Article
- Article
- Poloxamer 188 stabilized poly (ε-caprolactone) microspheres of voriconazole for targeting pulmonary aspergillosis.Therapeutic delivery · 2025Article
- Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate.The Journal of antimicrobial chemotherapy · 2024Article
- Utility of Itraconazole in Combination with Liposomal Amphotericin B in Rhizopus oryzae Associated Mucormycosis-An Exploratory Study.Mycopathologia · 2024Article
- Invasive fungal infections and oomycoses in cats 2. Antifungal therapy.Journal of feline medicine and surgery · 2024Review
- Surfactin and Capric Acid Affect the Posaconazole Susceptibility ofInternational journal of molecular sciences · 2023Article
- Successful Use of Fosmanogepix for Treatment of Rare Highly Resistant Cutaneous Fusariosis in a Pediatric Patient With STAT3 Hyper-Immunoglobulin E Syndrome and End-Stage Kidney Disease.Open forum infectious diseases · 2023Article
- Non-Journal of fungi (Basel, Switzerland) · 2023Review
- Echinocandins - structure, mechanism of action and use in antifungal therapy.Journal of enzyme inhibition and medicinal chemistry · 2022Review
- Management of Filamentous Fungal Keratitis: A Pragmatic Approach.Journal of fungi (Basel, Switzerland) · 2022Review
- Molecular Characterization and Antifungal Susceptibility ofTropical medicine and infectious disease · 2022Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the in vitro activity of caspofungin, posaconazole, voriconazole, ravuconazole, itraconazole, and amphotericin B against 448 recent clinical mold isolates. The endpoint for reading caspofungin was the minimum effective concentration (MEC). Among the triazoles, posaconazole was most active, inhibiting 95% of isolates at <or=1 microg/ml, followed by ravuconazole (91%), voriconazole (90%), and itraconazole (79%). Caspofungin and amphotericin B inhibited 93% and 89% of isolates at <or=1 microg/ml, respectively, with caspofungin demonstrating an MEC 90 of 0.12 microg/ml. All three new triazoles and caspofungin inhibited >95% of Aspergillus spp. at <or=1 microg/ml compared to 83% for itraconazole and 91% for amphotericin B. Amphotericin B inhibited only 38% of Aspergillus terreus isolates at <or=1 microg/ml, whereas the three new triazoles and caspofungin inhibited all A. terreus at <or=0.5 microg/ml. The new triazoles and caspofungin have excellent in vitro activity against a very large collection of recent clinical isolates of Aspergillus spp., and some in vitro activity against selected other filamentous fungi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.